Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge of the trial ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

Also Read: Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss In interviews with Reuters, some investors, analysts, and trial participants have raised concerns over CagriSema's ...

Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $81.

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...